Pregabalin + Placebo for pregabalin

Pre-clinicalTerminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Cord Injuries

Conditions

Spinal Cord Injuries

Trial Timeline

Feb 1, 2007 → Oct 1, 2008

About Pregabalin + Placebo for pregabalin

Pregabalin + Placebo for pregabalin is a pre-clinical stage product being developed by Pfizer for Spinal Cord Injuries. The current trial status is terminated. This product is registered under clinical trial identifier NCT00978341. Target conditions include Spinal Cord Injuries.

What happened to similar drugs?

7 of 20 similar drugs in Spinal Cord Injuries were approved

Approved (7) Terminated (1) Active (12)
🔄Ropivacaine + BupivacaineAstraZenecaPhase 3
🔄onasemnogene abeparvovecNovartisPhase 3

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00978341Pre-clinicalTerminated

Competing Products

20 competing products in Spinal Cord Injuries

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
35
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
42
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
36
ElezanumabAbbViePre-clinical
30
Elezanumab + PlaceboAbbViePhase 2
35
Ropivacaine + BupivacaineAstraZenecaPhase 3
40
Onasemnogene Abeparvovec-xioiNovartisPhase 1
21
ZolgensmaNovartisPre-clinical
33
BVS857 + PlaceboNovartisPhase 2
35
AVXS-101NovartisPhase 1
29
Onasemnogene Abeparvovec-xioiNovartisPhase 3
44
Onasemnogene Abeparvovec-brveNovartisApproved
50
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
30
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
branaplamNovartisPhase 1/2
32
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
onasemnogene abeparvovecNovartisPhase 3
47
onasemnogene abeparvovec-xioiNovartisPhase 3
40
RisdiplamRochePhase 1
29